]>
IRCT20151227025726N16 IRCT 2020-05-28 Shahid Beheshti University of Medical Sciences Evaluating the effect of ubiquinone (CoQ10) on the prevention of Acute Renal Injury following open heart surgery Evaluating the effect of ubiquinone (CoQ10) on the prevention of postoperative Acute Kidney Injury (AKI) following Coronary Artery Bypass Grafting surgery (CABG) 2016-06-19 anticipated 50 Complete https://irct.ir/trial/21468 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization method using table of random numbers is applied to the study population. Unit of randomization is individual. Even and odd numbers are chosen for the case and the control group, respectively. Numbered drug containers are applied for allocation concealment. 3 Acute Kidney Injury. Intervention 1: Intervention group: administration of ubiquinone oral tablets, 300 mg, 2 times a day (every 12 hours), for 2 days (48 hours before surgery). Intervention 2: Control Group: will not receive the drug . Yes - There is a plan to make this available What will be shared: All potential data can be shared after blinding. When: Six months after results publishing To whom: Researchers working in academic institutions Conditions: For research purposes and meta-analysis studies Where to obtain: Dr. Farzaneh Dastan, Masih Daneshvari Hospital, Daar-Abad, Niavaran How to obtain: Official letter to the researchers Comments:
public Alireza Jahangirifard
Masih Daneshvari Hospital, Daar-Abad, Shahid Bahonar St. (Niavaran)
Tehran Iran (Islamic Republic of) 1956944413 +98 21 2712 3000 alirezajahangiri@sbmu.ac.ir Masih Daneshvari Hospital scientific Farzaneh Dastan
Valieasr St., Intersection of Niyayesh Highway, Shahid Beheshti University of Medical Sciences, Faculty of Pharmacy
Tehran Iran (Islamic Republic of) 1991953381 +98 21 8820 0118 fzh.dastan@gmail.com Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) The patients who are candidates for Coronary Artery Bypass Graft surgery in Masih Daneshvari Hospital no limit no limit Both History of hypersensitivity reaction to ubiquinone Chronic liver failure (Stage II & III) Chronic kidney disease (Stage IV & V) or patients with Glomerular Filtration Rate of lower than 30 ml/min Patient with INR of more than 2.5 Patients who receive anti-inflammatory agents at least two weeks before admission Patients who undergo emergency CABG. N99.0 Postprocedural (acute) (chronic) kidney failure Prevention N/A Intervention group: administration of ubiquinone oral tablets, 300 mg, 2 times a day (every 12 hours), for 2 days (48 hours before surgery) Control Group: will not receive the drug . Acute Kidney Injury. Timepoint: before surgery and 6 & 24 hours after surgery. Method of measurement: Evaluation of NGAL kits. Checking of inflammatory biomarkers. Timepoint: before surgery and 24 hours after surgery. Method of measurement: Evalution of CRP kit. Shahid Beheshti University of Medical Sciences Approved 2016-03-01 Ethics committee of School of Pharmacy, Nursing, and Midwifery; Shahid Beheshti University of Medica No. 2660, Vali-e Asr St., Niyayesh Junction, Tehran Tehran Tehran Iran (Islamic Republic of)